Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jin Youli for secondary prevention of neutropenia in advanced pancreatic cancer
NCT04518800Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2020
- Primary completion
- Aug 2021
- Countries
- 1
01
Overview
Open-label, single-arm trial of pegfilgrastim in neutropenia, sponsored by Chinese PLA General Hospital. Primary endpoint: Incidence of degree 3-4 neutropenia in each cycle of chemotherapy at 12 weeks. Status: unknown.
02
Drugs
pegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT04518800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04518800.